...simply don’t have. Instead, AI assistants help streamline workflows. Practitioners can use voice commands or chat interfaces to ask the software to retrieve medical information from verified sources. These tools can transcribe patient-doctor telehealth consultations and summarize calls, helping practitioners keep accurate, organized records. Seamless integration with electronic health records (EHRs), PDMP databases, and other healthcare systems ensures a patient’s complete medical history, prevents outdated data issues, and reduces the risk of doctor shopping. All training data and patient record storage must meet HIPAA regulations to keep patients’ records confidential and eliminate the risk of a data breach. While the... Continue Reading
Search Results for data-security
News roundup: MSK is ‘it’ with Hinge Health’s IPO filing, Vori Health’s $53M raise, Dario Health’s 33% revenue increase; CoachCare buys VitalTech, ModMed investor sells majority stake, Health NZ uses Excel–only; Holmes gets rehearing extension
...Ventures, Echo Health Ventures, and Max Ventures, bringing their total funding since 2020 to $109 million. Vori’s model is physician-led with patients working with a virtual care team organizing care from diagnosis to therapy, prescriptions, labs, and imaging. They claim results of 91.6% of patients reporting clinically significant pain improvement, 78-90% reduction in elective orthopedic surgeries, a 42% decrease in opioid utilization, and up to a 68% reduction in depression and anxiety among patients. The funding will be used to deepen its value-based care initiatives (including evolving toward models with two-sided population health risk), invest in advanced data analytics for... Continue Reading
Update: Wojcicki increases 23andMe per share offer to $2.94 from $0.41–but there’s three contingency ‘catches’, and more
...genomic information that users cannot claw back or provably deidentify [TTA 8 Nov 2024] but would be attractive to other buyers–even if litigated. As to 23andMe’s future, the whole area of genomics now has multiple competitors including Big Pharma. There were reasons why GSK walked away from their foundational deal with the company. AI can work with current data, there’s no consumer hook to capture additional data, and the whole shebang is incredibly capital intensive. Are these revenue projections even feasible? 23andMe may have used up all its future–and Anne Wojcicki could be throwing away what remains of her fortune.... Continue Reading
Perspectives: How the DEA Telehealth Extension Impacts Patient Access to Opioid Use Disorder Treatments & Buprenorphine Prescriptions
...2020, permitting providers to prescribe buprenorphine via telehealth platforms and waiving the required initial in-person visit. Later-released studies that analyzed patient data for “low-threshold” buprenorphine treatment programs, many of which were offered at COVID-19 isolation sites and out of mobile vans, revealed that telemedicine showed much promise in successfully engaging patients from different socioeconomic backgrounds. This included rural residents, veterans, and homeless individuals seeking continued buprenorphine-based treatment. Such telehealth programs were reported to have high patient engagement numbers in the areas of acceptability and feasibility. For instance, many feasibility studies reported a 60% or higher rate of continued engagement after... Continue Reading
Breaking: 23andMe sale bids slide from $2.53 per share to $0.41 to none in 11 days, as board rejects CEO’s offer
...No one involved had any comments. (Share price today: $1.37) So the genetic data/testing/telemedicine company returns to Square Zero. One can only speculate why NMC withdrew so quickly, on what they saw after a bid that made them run, not walk, to the exit. One wonders how Anne Wojcicki would offer not only a misfire of a bid, but also counter with a ridiculously low bid that she had to know would be rejected. Then again, one wonders what the board’s options really are, given the parlous state of their cash reserves. Will this be the second board that throws... Continue Reading
Short takes: a guide to HIMSS25, Google Watch clears loss of pulse detection, OpenEvidence’s AI-powered $75M raise, Retrieve Medical to buy Cúratus, HerMD women’s health closes
...content partnerships, to train next-generation LLMs, and grow its team of scientists. With total funding over $100 million, its valuation is now $1 billion. Mobihealthnews, CNBC Retrieve Medical plans to acquire Cúratus LLC. Both seem to be bootstrapped data companies, with Retrieve analyzing patient data from multiple sources using advanced natural language processing (NLP) in its Retrieve Dx product for providers to understand complex clinical histories and diagnose chronic conditions. It integrates with major EHRs. Cúratus provides to health plans and provider groups provider data management, and governance for the Medicare Advantage, Medicaid, and commercial payer markets through its ProviderLenz... Continue Reading
Teladoc responds to Blue Orca’s report on BetterHelp’s AI ‘therapy’ (updated)
...will not be commented on here. Disclosure: Teladoc reached out to this Editor, supplying information about their response including the King & Spalding letter. This Editor hopes, and would like to see confirmation, that any BetterHelp therapist using third-party AI to respond to patients in providing direct therapy, versus Teladoc/BetterHelp supplied management tools, customer service information, or security tools, is disciplined and released. The integrity, privacy, and security of a telementalhealth platform is essential to its operation and the confidence of its patients–and should be publicly confirmed. Update: In response to this article, a spokesperson from Teladoc Health further elaborated:... Continue Reading
The wrapup line on ViVE
...smart, borderline scary smart”–especially AI agents being trained on “serious healthcare data and workflows”. Vendors are layering their workflows on top of off-the-shelf AI agents and the speed to market is “blinding”. Investment is up too with less ‘hand to mouth.’ Announcements, heavy on the AI, made during ViVE and recapped in MedCity News: Data analytics firm MultiPlan rebranded as Claritev. The company provides payments and pricing solutions based on healthcare claims data. It will start trading on the NYSE under CTEV next Friday 28 February. Release Abridge announced their $250 million Series D [TTA 21 Feb] Automation platform developer... Continue Reading
News roundup 21 Feb: UHG offers buyouts to 30K before layoffs (updated); more inside the Transcarent-Accolade deal; Hims acquires NJ testing company; layoffs bite inside HHS; in fundings, Vitalchat gains $6M, Frontera seeds at $32M, Harrison.ai $112M (AU), Abridge’s $250M
...return to 2020’s Big Raises. It was co-led by Lux Capital and Lightspeed Venture Partners, with Bison Ventures, Menlo Ventures, and Inspired Capital participating. Frontera specializes in autism services, including virtual autism diagnosis and assessments, as well as in-home and center-based ABA therapy. It uses what they call ‘digital phenotyping’ to analyze interactions and behaviors, providing real-time cognitive reasoning and objective data points for clinical assessments. Behavioral Health Business noted substantial raises by other companies such as Anna Health and Prosper Health, along with private equity (PE) investments. Release, Mobihealthnews Down Under, Harrison.ai’s Series C totaled $112 million in a... Continue Reading
News roundup 2: RFK Jr. confirmed as HHS Secretary, new MAHA commission formed; Amwell narrows loss by 68%; HEALWELL (CA) nears close of Orion Health (NZ) buy; Summer Health buys Caraway; Spectrum.Life (IE) plans to double users; 2025 NY Digital Health 100 announced
...health crisis, with an initial focus on childhood chronic diseases.” such as autism and fatty liver disease, plus adult asthma and the causes of the low US life expectancy. The EO’s four policy directives focus on reversing chronic disease through: transparency on health data to “avoid conflicts of interest in all federally funded health research prioritizing “gold-standard research on why Americans are getting sick” in all federally-funded health research working with farmers to ensure food is healthy as well as affordable expanding health coverage and treatment options “for beneficial lifestyle changes and disease prevention.” The timeframe is short: 100 days... Continue Reading
Most Recent Comments